文献速递青光眼小儿眼科与斜弱视

Aurolab房水引流植入物治疗难治性儿童青光眼的中期结局

Intermediate-term outcomes of Aurolab aqueous drainage implant in refractory paediatric glaucoma.
PubMed 文献 · Br J Ophthalmol · 2019-10-04

该研究回顾性分析2012至2015年间接受Aurolab房水引流植入物(AADI)手术的101只难治性儿童青光眼眼,随访超过2年。术后1年、2年、3年、4年累积失败概率分别为15.8%、22.7%、42.5%、62.1%,显示术后2年内成功率良好,之后失败率上升。作者认为需要更长期随访的前瞻性研究评估长期成功率。

要点

  • AADI术后1年累积失败概率15.8%,2年22.7%,2年内成功率良好。
  • 术后3年累积失败概率42.5%,4年升至62.1%,失败率随时间增加。
  • 白内障术后继发青光眼(30%)和原发性先天性青光眼(29%)是最常见类型。

核心结论

  • AADI在儿童难治性青光眼术后2年内显示良好成功率,之后失败率增加。
  • 作者认为需要进一步开展更长期随访的前瞻性研究来评估AADI用于儿童青光眼的长期成功率。

研究设计与样本

  • 回顾性分析2012年至2015年间接受AADI手术、随访超过2年的18岁以下患者病历记录。
  • 共纳入101例患者101只眼,手术时平均年龄10.4±4.7岁,平均随访40.9±15.1个月。
  • 在基线、术后第1天及术后1、3、6、9、12、18、24个月和末次随访时记录眼压、视力、抗青光眼药物数量、并发症及再次手术情况。

主要发现

  • 白内障术后继发性青光眼是最常见类型(n=31,30%),其次为原发性先天性青光眼(n=29,29%)。
  • 累积失败概率在1年为15.8%(95%CI 10.1%至24.5%),2年为22.7%(95%CI 15.7%至32.2%),3年为42.5%(95%CI 32.6%至53.9%),4年为62.1%(95%CI 49.5%至74.8%)。

关键数值与推荐

  • 失败定义为眼压>18 mm Hg或较基线未降低至少30%,或术后3个月后连续两次随访眼压≤5 mm Hg,或因并发症再次手术或丧失光感视力。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To report the intermediate-term outcomes of Aurolab aqueous drainage implant (AADI) surgery in paediatric eyes with refractory glaucoma. METHODS: Case records of patients below 18 years, who underwent AADI surgery between 2012 and 2015 with >2 years follow-up, were analysed. The intraocular pressure (IOP), visual acuity, number of antiglaucoma medications, complications and resurgery if any were recorded at baseline, day 1and then at months 1, 3, 6, 9, 12, 18, 24 and at the last visit. Failure was defined as IOP >18 mm Hg or not reduced by at least 30% below baseline, IOP ≤5 mm Hg on two consecutive follow-up visits after 3 months, reoperation for a complication or loss of light perception vision. RESULTS: 101 eyes of 101 patients were included with a mean age of 10.4±4.7 years at the time of surgery and a mean follow-up of 40.9±15.1 months. Glaucoma following cataract surgery was the most common type of glaucoma (n=31, 30%), followed by primary congenital glaucoma (n=29, 29%). The cumulative probability of failure was 15.8% (95% CI 10.1% to 24.5%) at 1 year, 22.7% (95% CI 15.7% to 32.2%) at 2 years, 42.5% (95% CI 32.6% to 53.9%) at 3 years and 62.1% (95% CI 49.5% to 74.8%) at the 4 years time point. CONCLUSION: The AADI showed excellent success until 2 years after surgery in paediatric eyes after which failure rates increased. Further prospective studies with longer follow-up are required to evaluate the long-term success of the AADI for paediatric glaucomas.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Puthuran GV, Palmberg PF, Wijesinghe HK, et al. Intermediate-term outcomes of Aurolab aqueous drainage implant in refractory paediatric glaucoma. Br J Ophthalmol. 2019. PMID: 31585962. doi:10.1136/bjophthalmol-2019-314399

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。